EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1 ‐ mutated acute myeloid leukaemia in molecular failure

C Sartor iD, L Brunetti, E Audisio, A Cignetti, L Zannoni, G Cristiano, J Nanni, R Ciruolo, F Zingarelli, E Ottaviani, A Patuelli, L Bandini und 7 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von C Sartor und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche e Chirurgiche, Istituto di Ematologia "Seràgnoli", Università degli Studi di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NPM1 ‐mutated acute myeloid leukaemia ( NPM1 mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although the negative prognostic role of pre‐HSCT MRD is established, no recommendations are available for the management of peri‐transplant molecular failure (MF). Based on the efficacy data of venetoclax (VEN)‐based treatment in NPM1 mut AML older patients, we retrospectively analysed the off‐label combination of VEN plus azacitidine (AZA) as bridge‐to‐transplant strategy in 11 NPM1 mut MRD‐positive fit AML patients. Patients were in MRD‐positive complete remission (CR MRDpos ) at the time of treatment: nine in molecular relapse and two in molecular persistence. After a median number of two cycles (range 1–4) of VEN–AZA, 9/11 (81.8%) achieved CR MRD ‐negative (CR MRDneg ). All 11 patients proceeded to HSCT. With a median follow‐up from treatment start of 26 months, and a median post‐HSCT follow‐up of 19 months, 10/11 patients are alive (1 died from non‐relapse mortality), and 9/10 patients are in MRD neg status. This patient series highlights the efficacy and safety of VEN–AZA to prevent overt relapse, achieve deep responses and preserve patient fitness before HSCT, in patients with NPM1 mut AML in MF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansAzacitidineNucleophosminRetrospective StudiesNeoplasm Recurrence, LocalChronic DiseaseRecurrenceNeoplasm, ResidualSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

AMLHSCTMRDvenetoclax

Substanzen

AzacitidineNucleophosminvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Dipartimento di Scienze Mediche e Chirurgiche, Istituto di Ematologia "Seràgnoli", Università degli Studi di Bologna, Bologna, Italy.
  • Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti delle Marche, Ancona, Italy.
  • SC Ematologia, Dipartimento di Ematologia e Oncologia, AO Città della Salute e della Scienza di Torino, Turin, Italy.
  • Department of Hematology and Cell Therapy, A.O. Ordine Mauriziano, Turin, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli" Bologna, Bologna, Italy.
  • Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.

ORCID-Profile: C Sartor, A Curti

Förderung

  • Ministero della Salute

Zitieren

APA

Sartor, C., Brunetti, L., Audisio, E., Cignetti, A., Zannoni, L., Cristiano, G., Nanni, J., Ciruolo, R., Zingarelli, F., Ottaviani, E., Patuelli, A., Bandini, L., Forte, D., Sciabolacci, S., Cardinali, V., Papayannidis, C., Cavo, M., Martelli, M. P., & Curti, A. (2023). A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1 ‐ mutated acute myeloid leukaemia in molecular failure. British Journal of Haematology. https://doi.org/10.1111/bjh.18887

Vancouver

Sartor C, Brunetti L, Audisio E, Cignetti A, Zannoni L, Cristiano G, et al. A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1 ‐ mutated acute myeloid leukaemia in molecular failure. British Journal of Haematology. 2023. doi:10.1111/bjh.18887

BibTeX
@article{Sartor2023,
  author = {Sartor, C and Brunetti, L and Audisio, E and Cignetti, A and Zannoni, L and Cristiano, G and Nanni, J and Ciruolo, R and Zingarelli, F and Ottaviani, E and Patuelli, A and Bandini, L and Forte, D and Sciabolacci, S and Cardinali, V and Papayannidis, C and Cavo, M and Martelli, M P and Curti, A},
  title = {A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1 ‐ mutated acute myeloid leukaemia in molecular failure},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18887}
}
Kostenlos starten →